Key result
Doxorubicin-loaded lipid nanoparticles achieved 78.5% tumor growth inhibition in a murine cancer model compared to 56.8% with free doxorubicin, alongside reduced systemic toxicity.
Why the study?
This study investigated the impact of lipid nanoparticles on enhancing the efficacy and reducing the toxicity of doxorubicin in cancer treatment.
Do doxorubicin-loaded lipid nanoparticles improve cytotoxicity and tumor growth inhibition compared to free doxorubicin in breast cancer cells and murine cancer models?
Do doxorubicin-loaded lipid nanoparticles improve cytotoxicity and tumor growth inhibition compared to free doxorubicin in breast cancer cells and murine cancer models?
Absolute Event Rate: 78.5% vs 56.8%
Doxorubicin-loaded lipid nanoparticles enhance antitumor efficacy and reduce systemic toxicity compared to free doxorubicin in preclinical models.
In vitro DOX-LNP data warrant further validation; leaves open clinical translation for doxorubicin delivery.
OBJECTIVE: This study investigates the impact of lipid nanoparticles on enhancing the efficacy and reducing the toxicity of doxorubicin in cancer treatment. METHODS: A high-pressure emulsification method prepared doxorubicin-loaded lipid nanoparticles (DOX-LNPs). Physicochemical properties were characterized, including particle size, zeta potential, and drug encapsulation efficiency. The cytotoxic effects of DOX-LNPs were evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay on MCF-7 breast cancer cells, while cellular uptake was assessed via fluorescence microscopy. In vivo , antitumor efficacy and systemic toxicity were analyzed in a murine cancer model. RESULTS: The synthesized nanoparticles had an average size of 148 nm and an encapsulation efficiency of 91.3%. In vitro , DOX-LNPs exhibited 1.8-fold higher cytotoxicity (lower IC₅₀) and 2.3-fold increased cellular uptake compared to free doxorubicin. In vivo , DOX-LNPs achieved 78.5% tumor growth inhibition, outperforming free doxorubicin (56.8%). Furthermore, systemic toxicity, including cardiotoxicity and nephrotoxicity, was significantly reduced in the DOX-LNP group compared to free doxorubicin. CONCLUSION: Lipid nanoparticles improve the therapeutic index of doxorubicin by enhancing its bioavailability and reducing off-target toxicity. These findings highlight their potential as an advanced drug delivery system, warranting further preclinical and clinical investigations.
No takes yet. Share an insight, caveat, or question.
Alrohaimi et al. (2025) studied Cancer. Doxorubicin-loaded lipid nanoparticles (DOX-LNPs) vs. Free doxorubicin was evaluated on Tumor growth inhibition. Doxorubicin-loaded lipid nanoparticles achieved 78.5% tumor growth inhibition in a murine cancer model compared to 56.8% with free doxorubicin, alongside reduced systemic toxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: